Trial · NCT03132155

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

NCT03132155, Phase 2, Terminated, NantPharma, LLC; results first posted 2024-05-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma. Trials, record NCT03132155. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03132155

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
NCT number: NCT03132155
Status: Terminated
Phases: Phase 2
Enrollment: 8 participants, actual
Lead sponsor: NantPharma, LLC
Conditions: Clear Cell Sarcoma
Interventions: AMG 337
First posted: 2017-04-27
Last updated: 2024-05-24
Results first posted: 2024-05-24
Limitations and caveats: The study was terminated early due to low enrollment. Only the safety data is provided.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Objective Response Rate (ORR)	1 year	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Secondary	Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability)	1 year	To evaluate the safety of AMG 337 based on grade 3 or 4 non-hematologic toxicity.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Objective Response Rate (ORR)	1 year		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability)	1 year		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Objective Response Rate (ORR)	AMG 337	Partial Response	1	Participants
Objective Response Rate (ORR)	AMG 337	Stable Disease	1	Participants
Objective Response Rate (ORR)	AMG 337	Progressive Disease	5	Participants
Objective Response Rate (ORR)	AMG 337	Imaging not available to evaluate	1	Participants
Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability)	AMG 337	Subjects with at Least 1 Grade 3 or 4 non-hematologic toxicity	6	Participants
Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability)	AMG 337	Subjects without Grade 3 or 4 non-hematologic toxicity.	2	Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	AMG 337	8
Overall Study	COMPLETED	AMG 337	0
Overall Study	NOT COMPLETED	AMG 337	8

Source ClinicalTrials.gov

Adverse events41

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Dry skin	Skin and subcutaneous tissue disorders	AMG 337	6	8
other	Rash	Skin and subcutaneous tissue disorders	AMG 337	3	8
other	Pruritus	Skin and subcutaneous tissue disorders	AMG 337	2	8
other	Palmar-plantar erythrodysaesthesia syndrome	Skin and subcutaneous tissue disorders	AMG 337	1	8
other	Rash pruritic	Skin and subcutaneous tissue disorders	AMG 337	1	8
other	Headache	Nervous system disorders	AMG 337	6	8
other	Dizziness	Nervous system disorders	AMG 337	1	8
other	Nausea	Gastrointestinal disorders	AMG 337	4	8
other	Abdominal pain	Nervous system disorders	AMG 337	2	8
other	Vomiting	Gastrointestinal disorders	AMG 337	2	8

1 to 10 of 41Source ClinicalTrials.gov

See all 41 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	AMG 337	4	8
Total, other adverse events	AMG 337	8	8
Total, serious adverse events	AMG 337	3	8

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03132155

GET https://conductscience.org/api/trials/v1/NCT03132155/events?page=2

API reference For AI assistants